Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +45.33% | +45.34% | +19.44% | +0.35% | +22.75% |
| Weighted Average Shares Diluted Growth | +45.33% | +45.34% | +19.44% | +0.35% | +22.75% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | -2.13% | +30.89% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +110.69% | +108.71% | -31.44% | -36.76% | -14.46% |
| Book Value per Share Growth | +47.25% | +44.66% | -47.67% | -43.51% | -42.91% |
| Debt Growth | -0.52% | -7.74% | -8.96% | -17.53% | -18.93% |
| R&D Expense Growth | +111.37% | +153.03% | +106.49% | +18.73% | +222.80% |
| SG&A Expenses Growth | +15.74% | +29.62% | +22.16% | -10.03% | +7.43% |